FDA panel backs much-debated ALS drug in rare, 2nd review

WASHINGTON — A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group.

Read more…

Please follow and like us: